Page 10 - Column Group News Today

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company...

Ribon Therapeutics, a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing. The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, John...

July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an over...

Circle Pharma Raises $66M in Series C Financing Circle Pharma, Inc., a South San Francisco, Calif.-based macrocycle drug discovery and development company focused on intractable cancer targets, raised $66m in Series C financing. The round was co-led by The Column Group and Nextech Invest with participation from Pandect Bioventures, together with new investors including Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and Eli Lilly and Company. The company intends to use the f...

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein...

Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR's ...

Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications News provided by Share this article Share this article LOS ANGELES, May 11, 2021 /PRNewswire/ -- Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HS...

Eikon Therapeutics closes $148M financing to develop super-resolution microscopy 06 May 2021 California-based firm to integrate advanced optics, machine learning with biochemistry; its target application is drug discovery. Eikon focuses on live-cell super-resolution microscopy for drug discovery.Eikon Therapeutics, a Hayward, California-based company focused on live-cell super-resolution microscopy and engineering for drug discovery, has this week announced that it has closed a $148 million S...

Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive. Shares0   Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening ,...

RTW Leads $106 Million Financing Round in Tenaya Therapeutics RTW Venture Fund Limited (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Tenaya Therapeutics, Inc. ("Tenaya") on 01 March 2021 of its completion of a $106 million Series C financing round led by RTW Investments, LP (the "Investment Manager"). The Company, alongside other...